Takeda Pharmaceutical (TAK) Operating Leases (2019 - 2020)
Takeda Pharmaceutical (TAK) posted Operating Leases of $601.4 million for Q3 2020, down 98.93% on a QoQ basis from $56.3 billion in Q1 2019.
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Operating Leases (2019 - 2020) Analysis & Trends
Takeda Pharmaceutical has reported Operating Leases for 2 years, with the latest figure at $601.4 million in Q3 2020.
- On a quarterly basis, Operating Leases changed N/A year-over-year to $601.4 million in Q3 2020; TTM through Sep 2020 was $601.4 million, a N/A change from a year earlier, with the FY2019 full-year figure at $56.3 billion, changed N/A from the prior year.
- Operating Leases was $601.4 million for Q3 2020 at Takeda Pharmaceutical, down from $56.3 billion in the prior quarter.
- The five-year high for Operating Leases was $56.3 billion in Q1 2019, with the low at $601.4 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn |
| 10 | Takeda Pharmaceutical | 2.62 Bn | -3.18 Bn | 5.10 Bn |